Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) has a beta value of 0.35 and has seen 111.84 million shares traded in the last trading session. The company, currently valued at $3.58M, closed the last trade at $0.46 per share which meant it gained $0.09 on the day or 24.02% during that session. The CYCC stock price is -769.57% off its 52-week high price of $4.00 and 32.61% above the 52-week low of $0.31. If we look at the company’s 10-day average daily trading volume, we find that it stood at 11.63 million shares traded. The 3-month trading volume is 1.64 million shares.
The consensus among analysts is that Cyclacel Pharmaceuticals Inc (CYCC) is Buy stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) trade information
Sporting 24.02% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CYCC stock price touched $0.46 or saw a rise of 48.31%. Year-to-date, Cyclacel Pharmaceuticals Inc shares have moved 22.34%, while the 5-day performance has seen it change 41.84%. Over the past 30 days, the shares of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) have changed 2.68%. Short interest in the company has seen 66765.0 shares shorted with days to cover at 0.03.
Wall Street analysts have a consensus price target for the stock at $1, which means that the shares’ value could jump 54.0% from current levels. The projected low price target is $1.0 while the price target rests at a high of $1.0. In that case, then, we find that the current price level is -117.39% off the targeted high while a plunge would see the stock gain -117.39% from current levels.
Cyclacel Pharmaceuticals Inc (CYCC) estimates and forecasts
The company’s shares have lost -71.43% over the past 6 months, compared to 16.90% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 32.13% over the past 5 years.
CYCC Dividends
Cyclacel Pharmaceuticals Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s Major holders
Insiders own 4.82% of the company shares, while shares held by institutions stand at 18.03% with a share float percentage of 18.94%. Investors are also buoyed by the number of investors in a company, with Cyclacel Pharmaceuticals Inc having a total of 19.0 institutions that hold shares in the company.
